Therapeutically, tumors with high PANoptosis scores exhibit greater tumor mutation burden (TMB), enhanced infiltration of CD8+ T and dendritic cells, and higher objective response rates (ORR) to PD-1/CTLA-4 inhibitors (42% vs 18%) (76, 79). This evidence concerns the gene CTLA4 and neoplasm.